Recruit Rockstars Podcast #367: How His VC-Backed Team Made Drug Development Faster

When creating new drugs, it’s often difficult to find enough patients for clinical trials.

And that limits the number of trials you can run.

Which slows down drug development. And costs lives.

Charles Fisher is out to change all that.

He’s CEO of Unlearn.AI

Based in San Francisco, Unlearn helps biopharma companies develop drugs more efficiently by leveraging AI to reduce the number of patients required for placebo controls in clinical trials.

In fact, Unlearn.AI enables clinical trials that are twice as fast, require fewer patients, produce better evidence about efficacy, and in which fewer patients need to be given placebos.

Last week, the company announced a major venture investment from Epic Ventures, Alumni Ventures Group, and the global Pharma company Eisai

Charles & his team are creating the first commercial product providing AI-derived Intelligent Control Arms to increase the statistical power of clinical trials, and accelerate study timelines in Alzheimer’s Disease.

In this 20-minute conversation, he reveals how he’s scaling the team.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.
Webinars

Applying Machine Learning to Increase Clinical Trial Efficiency: A Regulatory Journey

Press

Unlearn Closes $50 Million Series B Funding to Advance the Use of Its Machine Learning-Powered TwinRCTs™ in Clinical Trials

Press

Unlearn Signs Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany to Accelerate Immunology Trials using Twintelligent RCTs™

Collaborators will leverage AI-generated Digital Twins to enable smaller, more efficient pivotal clinical trials.
Led by Insight Partners, financing builds on the company’s momentum in working with leading biopharmaceutical companies to improve clinical trial efficiency.
Learn about the evolution of ideas that led to our TwinRCT™ solution for smaller, more efficient clinical trials and recent EMA draft qualification opinion.